52X Stock Chart & Stats
€1.49
€0.00(0.00%)
At close: 4:00 PM EST
€1.49
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €2.34
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.85M
Enterprise Value€440.40
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€356.15M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.76
Shares Outstanding30,263,191
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.92
Price to Sales (P/S)1.28
P/FCF Ratio-8.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.13
Revenue Forecast (FY)€34.73M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsThe company reports consistently very high gross margins, which is a durable structural advantage in pharmaceuticals. High product-level margins provide room to invest in R&D or absorb fixed-cost pressure from temporary demand dips, supporting long-term profitability potential if top-line stabilizes.
Integrated Services ModelMagle operates both drug development and manufacturing services for its own programs and external clients. This vertical, service-plus-product model diversifies revenue sources, enables recurring contract manufacturing relationships and cross-selling, and supports durable cash generation when demand is steady.
Moderate LeverageReported debt remains below equity, indicating the firm is not over-levered. Moderate leverage offers financial flexibility to fund operations or restructure without immediate solvency pressure, helping the company withstand cyclical downturns while it works to restore profitability.
Bears Say
Sustained Cash BurnOperating and free cash flows have been negative across multiple years, indicating the business is consuming cash rather than generating it. Persistent cash burn erodes reserves and equity, increases reliance on external financing, and constrains strategic investments or commercialization timelines over the medium term.
Recent Revenue ContractionRevenue momentum reversed to a sharp TTM decline after prior growth, signaling loss of demand or contracts. A shrinking top line undermines scale economics and makes it harder to convert high gross margins into operating profits, threatening long-term margin sustainability absent reacceleration.
Swing To Operating LossesThe company moved from profits to sizable operating losses and deeply negative net margins in 2025 and TTM. This persistent unprofitability erodes shareholder equity, limits reinvestment capacity, and raises refinancing and execution risk for development programs over the coming months.
Magle Chemoswed Holding AB News
52X FAQ
What was Magle Chemoswed Holding AB’s price range in the past 12 months?
Magle Chemoswed Holding AB lowest stock price was €0.06 and its highest was €2.34 in the past 12 months.
What is Magle Chemoswed Holding AB’s market cap?
Magle Chemoswed Holding AB’s market cap is €2.85M.
When is Magle Chemoswed Holding AB’s upcoming earnings report date?
Magle Chemoswed Holding AB’s upcoming earnings report date is Aug 05, 2026 which is in 10 days.
How were Magle Chemoswed Holding AB’s earnings last quarter?
Magle Chemoswed Holding AB released its earnings results on May 18, 2026. The company reported -€0.096 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Magle Chemoswed Holding AB overvalued?
According to Wall Street analysts Magle Chemoswed Holding AB’s price is currently Overvalued.
Does Magle Chemoswed Holding AB pay dividends?
Magle Chemoswed Holding AB does not currently pay dividends.
What is Magle Chemoswed Holding AB’s EPS estimate?
Magle Chemoswed Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Magle Chemoswed Holding AB have?
Magle Chemoswed Holding AB has 30,263,191 shares outstanding.
What happened to Magle Chemoswed Holding AB’s price movement after its last earnings report?
Magle Chemoswed Holding AB reported an EPS of -€0.096 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Magle Chemoswed Holding AB?
Currently, no hedge funds are holding shares in DE:52X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Magle Chemoswed Holding AB
Magle Chemoswed Holding AB (publ), based in Malmö, Sweden, specializes in the research, development, and manufacturing of products within the pharmaceutical chemistry and technology sectors. The company's core activities include the process development and production of Active Pharmaceutical Ingredients (APIs), as well as the innovation and manufacturing of advanced wound care and diagnostic products, primarily leveraging its proprietary degradable starch microsphere technology. Its API portfolio features Warfarin sodium, used as an anticoagulant; Melperone hydrochloride, an antipsychotic agent; Isradipine, a calcium channel blocker for hypertension; Amantadine sulfate, for central nervous system disorders; and Benserazide hydrochloride, utilized with L-Dopa in Parkinson's disease treatment. Furthermore, Magle Chemoswed offers a range of medical devices for advanced wound care, surgical diagnostics, and drug delivery. These include EmboCept S, a microsphere-based device for vascular occlusion in liver and lung tumors; SmartGel, an innovative non-allergenic hydrogel derived from their microsphere platform; SmartPAN, a diagnostic tool for detecting pancreatic fluid leakage during surgical procedures; and EmboCept M, designed for managing benign prostatic hyperplasia. The company provides contract services to the pharmaceutical and medical device industries. Founded in 1944, Magle Chemoswed Holding AB (publ) operates as a subsidiary of Magle AB.
Technical Analysis
Xbrane Biopharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Corline Biomedical AB
―